Ionis Pharmaceuticals Price Target Cut to $45.00/Share From $47.00 by JP Morgan
Ionis Pharmaceuticals Is Maintained at Neutral by JP Morgan
Ionis Pharmaceuticals Analyst Ratings
J.P. Morgan Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Cuts Target Price to $45
Ionis Pharmaceuticals: Strategic Partnerships and Financial Flexibility Drive Buy Rating
Oppenheimer Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Raises Target Price to $78
William Blair Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating
Ionis Pharmaceuticals (IONS) Receives a Buy From William Blair
J.P. Morgan Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Cuts Target Price to $47
Ionis Pharmaceuticals Analyst Ratings
JP Morgan Maintains Neutral on Ionis Pharmaceuticals, Lowers Price Target to $47
Stifel Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Maintains Target Price $38
Stifel Nicolaus Remains a Hold on Ionis Pharmaceuticals (IONS)
Bernstein Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Cuts Target Price to $43
Ionis Pharmaceuticals Is Maintained at Market Perform by BMO Capital
BMO Capital Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Cuts Target Price to $45
RBC Capital Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $70
Citi Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Cuts Target Price to $64
A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $38 to $70
Ionis Pharmaceuticals: Balancing Strong R&D Revenues With Market Challenges – Hold Rating Justified